Approval · Notice of Compliance 22694 · 2019
BAQSIMI: Notice of Compliance 22694
Issued September 25, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22694
- Date
- September 25, 2019
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BAQSIMI | 02492415 | Marketed |
Medicinal ingredients
- GLUCAGON 3 MG per DOSE